Blood Test Helps Determine Traumatic Brain Injury Severity
|
By LabMedica International staff writers Posted on 11 Aug 2015 |

Image: Three-dimensional structure of the brain-derived neurotrophic factor protein (Photo courtesy of Microswitch/ Protein Data Bank).
A new blood test could help emergency room doctors quickly diagnose traumatic brain injury and determine its severity and the test could help identify patients who might benefit from extra therapy or novel treatments.
Brain derived neurotrophic factor (BDNF) is important for neuronal survival and regeneration the diagnostic and prognostic values of serum BDNF in traumatic brain injury (TBI) and its association with two other proteins has been investigated.
A large group of collaborating scientists led by those at Johns Hopkins University School of Medicine (Baltimore, MD, USA) examined serum BDNF in two independent cohorts of TBI cases presenting to the emergency departments. At Johns Hopkins Hospital, 76 patients were studied and at San Francisco General Hospital (CA, USA), 80 patient were included in the study and a control group of 150 patients without TBI were enrolled.
The teams investigated the association between BDNF, Glial fibrillary acidic protein (GFAP) and Ubiquitin C-terminal hydrolase -L1 (UCH-L1) and recovery from TBI at six months in a pilot cohort. The investigators found that the levels of BDNF, taken within 24 hours of someone's head injury, could predict the severity of a TBI and how a patient would fare. While healthy people averaged 60 ng/mL of BDNF in their bloodstreams, patients with brain injuries had less than one-third of that amount, averaging less than 20 ng/mL, and those with the most severe TBIs had even lower levels, around 4 ng/mL. Moreover, patients with high levels of BDNF had mostly recovered from their injuries six months later, but in patients with the lowest levels of BDNF, symptoms still lingered at follow-up. The results suggest that a test for BDNF levels, administered in the emergency room, could help stratify patients.
Frederick Korley, MD, PhD, an assistant professor of emergency medicine and first author of the study said, “Compared to other proteins that have been measured in traumatic brain injury, BDNF does a much better job of predicting outcomes. The advantage of being able to predict prognosis early on is that you can advise patients on what to do, recommend whether they need to take time off work or school, and decide whether they need to follow up with a rehab doctor or neurologist.” The study was published on July 10, 2015, in the Journal of Neurotrauma.
Related Links:
Johns Hopkins University School of Medicine
San Francisco General Hospital
Brain derived neurotrophic factor (BDNF) is important for neuronal survival and regeneration the diagnostic and prognostic values of serum BDNF in traumatic brain injury (TBI) and its association with two other proteins has been investigated.
A large group of collaborating scientists led by those at Johns Hopkins University School of Medicine (Baltimore, MD, USA) examined serum BDNF in two independent cohorts of TBI cases presenting to the emergency departments. At Johns Hopkins Hospital, 76 patients were studied and at San Francisco General Hospital (CA, USA), 80 patient were included in the study and a control group of 150 patients without TBI were enrolled.
The teams investigated the association between BDNF, Glial fibrillary acidic protein (GFAP) and Ubiquitin C-terminal hydrolase -L1 (UCH-L1) and recovery from TBI at six months in a pilot cohort. The investigators found that the levels of BDNF, taken within 24 hours of someone's head injury, could predict the severity of a TBI and how a patient would fare. While healthy people averaged 60 ng/mL of BDNF in their bloodstreams, patients with brain injuries had less than one-third of that amount, averaging less than 20 ng/mL, and those with the most severe TBIs had even lower levels, around 4 ng/mL. Moreover, patients with high levels of BDNF had mostly recovered from their injuries six months later, but in patients with the lowest levels of BDNF, symptoms still lingered at follow-up. The results suggest that a test for BDNF levels, administered in the emergency room, could help stratify patients.
Frederick Korley, MD, PhD, an assistant professor of emergency medicine and first author of the study said, “Compared to other proteins that have been measured in traumatic brain injury, BDNF does a much better job of predicting outcomes. The advantage of being able to predict prognosis early on is that you can advise patients on what to do, recommend whether they need to take time off work or school, and decide whether they need to follow up with a rehab doctor or neurologist.” The study was published on July 10, 2015, in the Journal of Neurotrauma.
Related Links:
Johns Hopkins University School of Medicine
San Francisco General Hospital
Latest Clinical Chem. News
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- Blood Test Tracks Transplant Health Using Donor DNA
- New Blood Test Index Offers Earlier Detection of Liver Scarring
- Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
- Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care
- Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
Channels
Molecular Diagnostics
view channel
New Respiratory Panel Expands Pathogen Detection to 25 Targets
Respiratory infections often present with overlapping symptoms, complicating differential diagnosis in acute and community settings. The stakes are higher for older adults, young children, and people with... Read more
Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
Alzheimer’s disease affects millions worldwide but remains difficult to detect at its earliest, pre-symptomatic stage. Clinicians need tools that can identify biological changes before cognitive symptoms... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more








